MHRA Warns of Rare Eye Condition Linked to Semaglutide
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued an important update for healthcare professionals and patients regarding semaglutide, a medication widely used for treating type 2 diabetes and weight management. The agency has highlighted a very rare but serious risk of non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to sudden vision loss.
Understanding Semaglutide
Semaglutide is classified as a glucagon-like peptide-1 receptor agonist (GLP-1RA) and is marketed under the brand names Ozempic and Rybelsus for diabetes management, while also being referred to as Wegovy for weight loss and cardiovascular risk reduction purposes. It has been in use since 2018 and has gained immense popularity among patients managing these conditions.
What is NAION?
NAION is a highly uncommon condition characterized by reduced blood flow to the optic nerve, resulting in sudden, painless vision impairment in one eye. Individuals affected report experiencing visual disturbances such as blurring or cloudiness. Such symptoms warrant immediate medical attention, and patients on semaglutide experiencing vision changes are advised to seek urgent care at an eye casualty or accident and emergency department.
Your Safety is Paramount
Dr. Alison Cave, Chief Safety Officer for the MHRA, emphasized that ensuring patient safety is of paramount importance. While the risk of NAION associated with semaglutide is exceptionally low, it is crucial that patients and healthcare providers remain vigilant for symptoms related to this rare condition. Dr. Cave encourages users to report any sudden loss of vision to healthcare authorities and to utilize the Yellow Card scheme for this purpose.
Precautionary Steps and Further Information
In light of this advisory, the MHRA has published a Drug Safety Update aimed at informing healthcare practitioners about the potential risk of NAION in patients prescribed semaglutide. Studies indicate that the likelihood of developing this condition may be as low as 1 in 10,000 among users.
Within the UK, there have been only three reports of NAION associated with semaglutide since its initial approval, despite over 10 million packs being dispensed during this period. The MHRA is actively reviewing any connections between other GLP-1 receptor agonists and similar risks.
Reporting Adverse Effects
The MHRA urges anyone experiencing suspected side effects from semaglutide or other medications to report these through the Yellow Card scheme, available on their website or via the MHRA app found in app stores.
Source: official statements, news agencies, and public reports.
https://www.gov.uk/government/news/mhra-updates-guidance-for-semaglutide-prescribers-and-patients
